LogicBio Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1/2 SUNRISE Clinical Trial for the Treatment of Pediatric Patients Suffering from Methylmalonic Acidemia
June 2, 2021 at 7:00 AM EDT
PDF Version - Company believes dosing represents first in vivo gene editing therapy delivered systemically to a pediatric patient - Clinical trial designed to treat patients as young as 6 months old with LB-001 based on proprietary GeneRide™ platform - Company remains on track to announce update on enrollment, dose escalation and age de-escalation in late 2021 and interim data by year-end 2021
Comments